BioSpace News Archive

Antios Therapeutics, Inc. (“Antios”) today announced that the Company is presenting in vitro and Phase 1a data on ATI-2173

Ryvu Therapeutics announced the online publication of two posters and an oral presentation demonstrating clinical and pre-clinical activity of its selective CDK8/19 inhibitor RVU120 and the dual PIM/FLT3 inhibitor SEL24, in-licensed by Menarini Group from Ryvu Therapeutics, at the Annual European Hematology Association 2021 Virtual Congress.

Novan, Inc., announced positive topline efficacy and safety results for the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum.

Orthofix Medical Inc., a global medical device company with a spine and orthopedics focus, announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the upcoming JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 11:00 a.m. ET.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of Tempol.

BioVie Inc. (NASDAQ: BIVI) (“BioVie” or “Company”) today announced the closing of its previously announced acquisition of the biopharmaceutical assets of NeurMedix, Inc.

Oryzon Genomics, S.A.presented today new positive efficacy data from its ongoing Phase IIa ALICE trial.

Genetic Technologies Limited, a diversified Genomics and AI driven preventative health business, has been granted US Patent No. 11,031,098 – ‘Computer Systems and Methods for Genomic Analysis’.

ReCode Therapeutics Presents Preclinical Data Using SORT-LNP ™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS).

Medexus Pharmaceuticals Inc. today announced that it plans to host a conference call at 8:00 AM Eastern Time on Thursday, June 17, 2021 to discuss the Company’s financial results for the fiscal year-ended March 31, 2021.